51.33

0.52% -0.27

After Hours: 52.00 0.67 +1.31%

Corcept Therapeutics Inc (CORT)

Overview News Price History Option Chain Financials Why CORT Down? Discussions Forecast

Corcept Therapeutics Inc stock is traded at $51.33, with a volume of 1.18M. It is down -0.52% in the last 24 hours and up +20.80% over the past month. Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Previous Close:

$51.60

Open:

$52.165

24h Volume:

1.18M

Relative Volume:

0.69

Market Cap:

$5.51B

Revenue:

$761.41M

Net Income/Loss:

$98.16M

P/E Ratio:

62.74

EPS:

0.8181

Net Cash Flow:

$141.79M

1W Performance:

+10.10%

1M Performance:

+20.80%

6M Performance:

-33.03%

1Y Performance:

-30.58%

1-Day Range:

$51.00

$52.16

1-Week Range:

$45.73

$52.50

52-Week Range:

$28.66

$91.00

Corcept Therapeutics Inc Stock (CORT) Company Profile

Name

Corcept Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

650.688.8803

Address

101 REDWOOD SHORES PARKWAY, REDWOOD CITY

Employee

730

Twitter

Next Earnings Date

2026-04-30

Latest SEC Filings

CORT's Discussions on Twitter

Compare CORT vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CORT Corcept Therapeutics Inc	51.33	5.54B	761.41M	98.16M	141.79M	0.8181
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-26-26	Upgrade	Wolfe Research	Underperform → Peer Perform
Dec-31-25	Downgrade	Wolfe Research	Peer Perform → Underperform
Dec-16-25	Initiated	UBS	Neutral
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Nov-06-23	Upgrade	Truist	Hold → Buy
Apr-11-23	Initiated	SVB Securities	Market Perform
Apr-04-23	Initiated	Piper Sandler	Overweight
Feb-15-23	Downgrade	Jefferies	Buy → Hold
Aug-01-22	Downgrade	Truist	Buy → Hold
Jul-27-22	Upgrade	Jefferies	Hold → Buy
Jun-27-22	Resumed	Canaccord Genuity	Buy
Feb-02-22	Initiated	Canaccord Genuity	Buy
Jan-28-22	Initiated	Truist	Buy
Aug-05-20	Downgrade	Jefferies	Buy → Hold
Sep-24-19	Initiated	Jefferies	Buy
Sep-06-19	Initiated	H.C. Wainwright	Buy
Feb-04-19	Downgrade	B. Riley FBR	Buy → Neutral
Aug-10-18	Reiterated	Stifel	Hold
May-31-18	Downgrade	Stifel	Buy → Hold
Mar-09-18	Initiated	B. Riley FBR, Inc.	Buy
Aug-31-17	Initiated	Stifel	Buy
Feb-02-17	Initiated	Ladenburg Thalmann	Buy
Apr-21-15	Initiated	FBR Capital	Outperform
Jan-13-14	Downgrade	Stifel	Buy → Hold
Aug-09-13	Downgrade	Janney	Buy → Neutral
Aug-09-13	Downgrade	Ladenburg Thalmann	Buy → Neutral
Feb-21-12	Reiterated	JMP Securities	Mkt Outperform
Jan-06-10	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jul-17-08	Initiated	Rodman & Renshaw	Mkt Outperform
Jun-21-07	Upgrade	Punk, Ziegel & Co	Mkt Perform → Accumulate

View All

Corcept Therapeutics Inc Stock (CORT) Latest News

04:30 AM

Corcept (NASDAQ: CORT) CEO sells 40K shares under 10b5-1 plan - Stock Titan

04:30 AM

11:13 AM

Corcept Therapeutics (NASDAQ: CORT) affiliate plans sale of 20,000 shares via Stifel - Stock Titan

11:13 AM

08:21 AM

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2026 Earnings Call Transcript - Insider Monkey

08:21 AM

May 04, 2026

Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo

May 04, 2026

H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $75 - Moomoo

May 04, 2026

CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures - TradingView

May 04, 2026

CORT Maintained by HC Wainwright & Co. -- Price Target Raised to $75 - GuruFocus

May 04, 2026

CORT DEADLINE: ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class ActionCORT - TMX Newsfile

May 04, 2026

May 03, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 03, 2026

MSN Money - MSN

May 03, 2026

May 02, 2026

Corcept (CORT) Upgraded After Key Regulatory Approval for Lifyorli - Yahoo Finance

May 02, 2026

May 01, 2026

Corcept Therapeutics Shakes Up Nasdaq Index Fund Radar - Kalkine Media

May 01, 2026

CORT Maintained by Piper Sandler -- Price Target Raised to $88 - GuruFocus

May 01, 2026

Corcept Therapeutics Guides Higher on Lifyorli-Fueled Revenue Growth - The Globe and Mail

May 01, 2026

Corcept Therapeutics Is Maintained at Overweight by Piper Sandler - Moomoo

May 01, 2026

Corcept Therapeutics (NASDAQ:CORT) Stock Price Up 7.9%Time to Buy? - MarketBeat

May 01, 2026

Corcept Therapeutics (CORT) insider notifies sale of 40,000 shares via Stifel - Stock Titan

May 01, 2026

CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised - The Globe and Mail

May 01, 2026

Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk - Benzinga

May 01, 2026

Corcept Therapeutics Incorporated Q1 2026 Earnings Call Summary - Yahoo Finance

May 01, 2026